- |||||||||| belrestotug (EOS-448) / iTeos, GSK, nelistotug (GSK6097608) / GSK, Jemperli (dostarlimab-gxly) / GSK
Enrollment closed: GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov) - May 28, 2025 P2, N=351, Active, not recruiting, Recruiting --> Active, not recruiting
- |||||||||| GSK4381562 / GSK
Trial completion date, Trial primary completion date, Monotherapy: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 12, 2024 P1, N=141, Recruiting, Recruiting --> Completed | Trial completion date: Jul 2025 --> May 2024 | Trial primary completion date: Jul 2025 --> May 2024 Trial completion date: Oct 2026 --> Sep 2028 | Trial primary completion date: Oct 2026 --> Sep 2028
- |||||||||| 23ME-00610 / 23andMe
New insights into targeting the CD200R1 pathway in T and NK cells using 23ME-00610 as a single agent or in combination (Section 38) - Mar 5, 2024 - Abstract #AACR2024AACR_3752; P1/2 Taken together, these data demonstrate that 23ME-00610 can enhance both NK and T cell antitumor effector functions, and 23ME-00610 could synergize with anti-PD-1 to further increase the activity of T cells against cancer cells. The results of this study provide evidence that 23ME-00610 could expand IO treatment options for patients with advanced solid malignancies as a single agent or in combination with other anti-tumor therapeutics.
- |||||||||| nelistotug (GSK6097608) / GSK
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 31, 2023 P1, N=244, Recruiting, Trial completion date: Mar 2026 --> Jan 2028 N=184 --> 244 | Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025
- |||||||||| belrestotug (EOS-448) / iTeos, GSK, nelistotug (GSK6097608) / GSK, Jemperli (dostarlimab-gxly) / GSK
Trial completion date, Trial primary completion date: GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Sep 7, 2023 P2, N=300, Recruiting, The clinical PK, PD, safety, and translational data support evaluation of 23ME-00610 1400 mg Q3W in the ongoing Phase 2a. Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Jan 2025
- |||||||||| GSK4381562 / GSK
Trial completion date, Trial primary completion date, Monotherapy: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2023 P1, N=162, Recruiting, Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
- |||||||||| nelistotug (GSK6097608) / GSK
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 23, 2023 P1, N=184, Recruiting, Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026 Trial completion date: Apr 2025 --> Jul 2024 | Trial primary completion date: Apr 2025 --> Jul 2024
- |||||||||| nelistotug (GSK6097608) / GSK
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2023 P1, N=184, Recruiting, Trial completion date: Apr 2025 --> Jul 2024 | Trial primary completion date: Apr 2025 --> Jul 2024 Trial completion date: Aug 2024 --> Apr 2025 | Trial primary completion date: Aug 2024 --> Apr 2025
- |||||||||| belrestotug (EOS-448) / iTeos, GSK, GSK6097608 / GSK, Jemperli (dostarlimab) / GSK
Phase II study of anti-TIGIT GSK4428859A (GSK'859A)/EOS-448 + anti-CD96 GSK6097608 (GSK'608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3256; P1, P1/2, Patients will receive IV GSK'859A/EOS-448 + dostarlimab + GSK'608 (dose escalation) q3w for ≤35 cycles or 2 years or until disease progression, consent withdrawal, intolerability, or death. Part 1 endpoints are safety and tolerability (primary) and efficacy and pharmacokinetics (secondary).
- |||||||||| nelistotug (GSK6097608) / GSK
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 18, 2022 P1, N=178, Recruiting, Part 1 endpoints are safety and tolerability (primary) and efficacy and pharmacokinetics (secondary). Trial completion date: Feb 2023 --> Aug 2024 | Trial primary completion date: Feb 2023 --> Aug 2024
- |||||||||| GSK4381562 / GSK
Enrollment open, Trial completion date, Trial primary completion date, Monotherapy: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 3, 2022 P1, N=126, Recruiting, Trial completion date: Feb 2023 --> Aug 2024 | Trial primary completion date: Feb 2023 --> Aug 2024 Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Feb 2027 | Trial primary completion date: Feb 2023 --> Oct 2024
|